Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.08.2018 | Case report

Rituximab

Chest infection and wound infection: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat So H, et al. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clinical Rheumatology 37: 1983-1989, No. 7, Jul 2018. Available from: URL: http://doi.org/10.1007/s10067-018-4122-2http://doi.org/10.1007/s10067-018-4122-2 - Hong KongCrossRefPubMed So H, et al. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clinical Rheumatology 37: 1983-1989, No. 7, Jul 2018. Available from: URL: http://​doi.​org/​10.​1007/​s10067-018-4122-2http://​doi.​org/​10.​1007/​s10067-018-4122-2 - Hong KongCrossRefPubMed
Metadaten
Titel
Rituximab
Chest infection and wound infection: 3 case reports
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-50141-6

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Antineoplastics

Case report

Vemurafenib

Case report

Pyridoxine